Consortium's US$0.02-a-share cash bid for Aino Health enters final stretch
What's the deal? HealthCo Oy has published a supplement to its offer document for a recommended public cash offer to buy all shares in Aino Health AB it does not already hold, at US$0.02 per share. HealthCo, known as BidCo, is acting for a consortium of eight members, including Nexit III Ky, Tenendum Oy, and Aino Health chief executive officer Marc Josefsson.
Why now? The supplement, published August 3, 2026, adds Aino Health's half-year report for the period January 1 to June 30, 2026, released the same day. It updates shareholders with fresh financials while the offer is still live.
What changes for shareholders? The offer period runs from July 1 to August 10, 2026, unless extended. Aino Health, listed on Nasdaq First North Growth Market in Sweden, would move into consortium ownership if the bid succeeds.
The signal: A recommended take-private at US$0.02 a share, backed partly by the target's own chief executive officer, points to a company seeking to exit the public market and restructure away from the scrutiny of small-cap trading. The mid-offer supplement, timed to the half-year report, is a reminder that shareholders weighing the deal now have current numbers to judge it against.
Read more: MFN
Image credit: startupregistry.hk
